Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Humana Inc. operating profit margin ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Humana Inc. net profit margin ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Humana Inc. ROE deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
ROA | A profitability ratio calculated as net income divided by total assets. | Humana Inc. ROA deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Operating Profit Margin
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Income from operations | 728) | 1,141) | 1,236) | (348) | 1,206) | 1,436) | 1,719) | 124) | 1,172) | 1,215) | 1,289) | 61) | 628) | 1,236) | 1,223) | (346) | 1,823) | 2,435) | 1,074) | 362) | 868) | 1,115) | 847) | |||||||
External revenues | 29,054) | 29,242) | 29,323) | 26,168) | 26,115) | 26,473) | 26,549) | 22,279) | 22,627) | 23,615) | 23,967) | 21,088) | 20,730) | 20,469) | 20,590) | 18,848) | 19,361) | 19,006) | 18,786) | 16,145) | 16,105) | 16,131) | 16,006) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | 2.42% | 2.92% | 3.27% | 3.81% | 4.42% | 4.55% | 4.45% | 4.11% | 4.09% | 3.57% | 3.73% | 3.80% | 3.40% | 4.97% | 6.60% | 6.56% | 7.77% | 6.77% | 5.09% | 4.96% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 16.24% | 15.92% | 15.76% | 16.15% | 15.02% | 15.23% | 16.77% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | 13.39% | 12.78% | 14.18% | 14.21% | — | — | — | |||||||
Cigna Group | 4.02% | 4.14% | 4.29% | 4.40% | 4.34% | 4.38% | 4.54% | 4.69% | 4.59% | 4.71% | 4.64% | 4.60% | 4.59% | 4.57% | 4.98% | 5.12% | 5.37% | 5.47% | 5.18% | 5.31% | — | — | — | |||||||
CVS Health Corp. | 2.59% | 3.42% | 3.49% | 3.85% | 4.04% | 1.88% | 2.33% | 2.41% | 2.02% | 4.35% | 4.39% | 4.54% | 4.75% | 4.93% | 5.19% | 5.19% | 5.44% | 5.36% | 4.89% | 4.69% | — | — | — | |||||||
Elevance Health Inc. | 4.55% | 4.76% | 4.64% | 4.47% | 4.58% | 4.96% | 4.99% | 4.94% | 5.01% | 5.07% | 5.10% | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | 5.59% | 6.99% | 5.47% | 5.49% | — | — | — | |||||||
Intuitive Surgical Inc. | 26.24% | 25.79% | 25.26% | 24.80% | 24.66% | 24.34% | 24.21% | 25.35% | 27.05% | 28.48% | 30.69% | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | 23.95% | 25.86% | 30.52% | 30.69% | — | — | — | |||||||
Medtronic PLC | 17.50% | 17.41% | 17.83% | 17.56% | 18.17% | 19.02% | 19.37% | 18.15% | 17.89% | 16.68% | 14.78% | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | 20.67% | 20.47% | 21.25% | 20.51% | — | — | — | |||||||
UnitedHealth Group Inc. | 8.28% | 8.40% | 8.58% | 8.80% | 8.86% | 8.83% | 8.87% | 8.83% | 8.65% | 8.32% | 8.19% | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | 9.55% | 9.89% | 8.12% | 8.19% | — | — | — |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Operating profit margin = 100
× (Income from operationsQ3 2024
+ Income from operationsQ2 2024
+ Income from operationsQ1 2024
+ Income from operationsQ4 2023)
÷ (External revenuesQ3 2024
+ External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023)
= 100 × (728 + 1,141 + 1,236 + -348)
÷ (29,054 + 29,242 + 29,323 + 26,168)
= 2.42%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Humana Inc. operating profit margin ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Net Profit Margin
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income attributable to Humana | 480) | 679) | 741) | (541) | 832) | 959) | 1,239) | (15) | 1,195) | 696) | 930) | (14) | 1,531) | 588) | 828) | (274) | 1,340) | 1,828) | 473) | 512) | 689) | 940) | 566) | |||||||
External revenues | 29,054) | 29,242) | 29,323) | 26,168) | 26,115) | 26,473) | 26,549) | 22,279) | 22,627) | 23,615) | 23,967) | 21,088) | 20,730) | 20,469) | 20,590) | 18,848) | 19,361) | 19,006) | 18,786) | 16,145) | 16,105) | 16,131) | 16,006) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | 1.19% | 1.54% | 1.84% | 2.36% | 2.97% | 3.45% | 3.28% | 3.03% | 3.07% | 3.52% | 3.52% | 3.54% | 3.31% | 3.13% | 4.78% | 4.43% | 5.67% | 5.00% | 3.89% | 4.20% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 13.99% | 13.65% | 13.96% | 14.27% | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | 10.50% | 9.89% | 11.15% | 11.56% | — | — | — | |||||||
Cigna Group | 1.31% | 1.71% | 1.77% | 2.66% | 2.81% | 3.59% | 3.71% | 3.72% | 3.69% | 3.08% | 3.07% | 3.11% | 4.97% | 4.93% | 5.22% | 5.31% | 3.40% | 3.43% | 3.22% | 3.35% | — | — | — | |||||||
CVS Health Corp. | 1.37% | 1.99% | 2.04% | 2.34% | 2.48% | 0.86% | 1.20% | 1.29% | 1.00% | 2.66% | 2.68% | 2.72% | 2.67% | 2.60% | 2.74% | 2.68% | 3.00% | 3.14% | 2.77% | 2.59% | — | — | — | |||||||
Elevance Health Inc. | 3.72% | 3.93% | 3.66% | 3.52% | 3.63% | 3.89% | 3.89% | 3.87% | 4.09% | 4.13% | 4.37% | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | 4.26% | 5.27% | 4.42% | 4.66% | — | — | — | |||||||
Intuitive Surgical Inc. | 28.51% | 27.65% | 27.16% | 25.24% | 22.14% | 21.38% | 20.40% | 21.25% | 22.52% | 24.05% | 27.84% | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | 24.45% | 26.07% | 30.11% | 30.80% | — | — | — | |||||||
Medtronic PLC | 13.00% | 12.84% | 11.47% | 12.03% | 13.20% | 14.03% | 16.75% | 15.90% | 15.46% | 14.79% | 12.29% | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | 17.11% | 15.11% | 14.41% | 15.16% | — | — | — | |||||||
UnitedHealth Group Inc. | 3.68% | 3.70% | 4.09% | 6.09% | 6.09% | 6.11% | 6.21% | 6.25% | 6.21% | 5.99% | 5.91% | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | 6.66% | 6.94% | 5.63% | 5.76% | — | — | — |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Net profit margin = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ (External revenuesQ3 2024
+ External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023)
= 100 × (480 + 679 + 741 + -541)
÷ (29,054 + 29,242 + 29,323 + 26,168)
= 1.19%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Humana Inc. net profit margin ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Return on Equity (ROE)
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income attributable to Humana | 480) | 679) | 741) | (541) | 832) | 959) | 1,239) | (15) | 1,195) | 696) | 930) | (14) | 1,531) | 588) | 828) | (274) | 1,340) | 1,828) | 473) | 512) | 689) | 940) | 566) | |||||||
Stockholders’ equity | 17,565) | 16,671) | 16,130) | 16,262) | 16,949) | 16,834) | 16,577) | 15,311) | 16,254) | 15,490) | 15,319) | 16,080) | 16,260) | 14,843) | 14,190) | 13,728) | 15,768) | 14,416) | 12,355) | 12,037) | 11,601) | 11,872) | 10,841) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | 7.74% | 10.26% | 12.34% | 15.31% | 17.79% | 20.07% | 18.79% | 18.33% | 17.27% | 20.29% | 19.81% | 18.24% | 16.44% | 16.72% | 26.23% | 24.53% | 26.34% | 24.29% | 21.16% | 22.49% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 14.49% | 14.13% | 14.51% | 14.83% | 13.77% | 13.88% | 15.68% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | 10.78% | 10.17% | 11.84% | 11.86% | — | — | — | |||||||
Cigna Group | 7.22% | 8.97% | 8.79% | 11.17% | 11.61% | 14.64% | 15.17% | 14.86% | 14.69% | 11.94% | 11.69% | 11.39% | 17.68% | 16.73% | 17.52% | 16.81% | 11.03% | 11.11% | 10.91% | 11.26% | — | — | — | |||||||
CVS Health Corp. | 6.69% | 9.60% | 9.90% | 10.91% | 11.57% | 4.02% | 5.57% | 5.84% | 4.46% | 10.86% | 10.83% | 10.54% | 10.20% | 9.83% | 10.44% | 10.35% | 11.56% | 12.14% | 11.08% | 10.39% | — | — | — | |||||||
Elevance Health Inc. | 14.66% | 15.86% | 15.38% | 15.23% | 15.82% | 16.78% | 16.62% | 16.59% | 17.26% | 17.04% | 17.36% | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | 14.61% | 17.17% | 15.08% | 15.15% | — | — | — | |||||||
Intuitive Surgical Inc. | 14.39% | 14.23% | 14.24% | 13.51% | 12.10% | 12.00% | 11.70% | 11.98% | 11.97% | 11.93% | 13.58% | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | 11.38% | 13.00% | 16.30% | 16.69% | — | — | — | |||||||
Medtronic PLC | 8.11% | 7.97% | 7.07% | 7.30% | 7.90% | 8.33% | 9.88% | 9.59% | 9.35% | 9.05% | 7.54% | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | 10.26% | 9.23% | 8.78% | 9.25% | — | — | — | |||||||
UnitedHealth Group Inc. | 15.14% | 15.78% | 17.72% | 25.22% | 25.67% | 25.63% | 25.46% | 25.87% | 26.03% | 25.07% | 23.98% | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | 25.65% | 26.87% | 24.14% | 24.02% | — | — | — |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
ROE = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ Stockholders’ equity
= 100 × (480 + 679 + 741 + -541)
÷ 17,565 = 7.74%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Humana Inc. ROE deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Return on Assets (ROA)
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income attributable to Humana | 480) | 679) | 741) | (541) | 832) | 959) | 1,239) | (15) | 1,195) | 696) | 930) | (14) | 1,531) | 588) | 828) | (274) | 1,340) | 1,828) | 473) | 512) | 689) | 940) | 566) | |||||||
Total assets | 50,007) | 50,093) | 50,091) | 47,065) | 55,905) | 56,455) | 54,776) | 43,055) | 50,765) | 46,820) | 46,308) | 44,358) | 45,320) | 38,070) | 37,415) | 34,969) | 38,477) | 38,455) | 34,633) | 29,074) | 29,180) | 28,913) | 28,349) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | 2.72% | 3.42% | 3.97% | 5.29% | 5.39% | 5.98% | 5.69% | 6.52% | 5.53% | 6.71% | 6.55% | 6.61% | 5.90% | 6.52% | 9.95% | 9.63% | 10.79% | 9.11% | 7.55% | 9.31% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 7.76% | 7.61% | 7.77% | 7.82% | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | 4.90% | 4.52% | 5.36% | 5.43% | — | — | — | |||||||
Cigna Group | 1.93% | 2.39% | 2.36% | 3.38% | 3.54% | 4.43% | 4.56% | 4.63% | 4.59% | 3.59% | 3.53% | 3.46% | 5.44% | 5.29% | 5.55% | 5.44% | 3.31% | 3.30% | 3.18% | 3.28% | — | — | — | |||||||
CVS Health Corp. | 1.99% | 2.85% | 2.93% | 3.34% | 3.42% | 1.17% | 1.66% | 1.82% | 1.36% | 3.55% | 3.43% | 3.39% | 3.23% | 3.12% | 3.22% | 3.11% | 3.41% | 3.51% | 3.13% | 2.98% | — | — | — | |||||||
Elevance Health Inc. | 5.51% | 5.92% | 5.58% | 5.50% | 5.50% | 5.87% | 5.69% | 5.86% | 6.03% | 6.05% | 6.21% | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | 5.72% | 6.72% | 5.80% | 6.21% | — | — | — | |||||||
Intuitive Surgical Inc. | 12.64% | 12.57% | 12.56% | 11.64% | 10.31% | 10.25% | 10.05% | 10.19% | 10.39% | 10.47% | 12.02% | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | 9.92% | 11.24% | 14.02% | 14.17% | — | — | — | |||||||
Medtronic PLC | 4.63% | 4.55% | 3.99% | 4.13% | 4.32% | 4.63% | 5.79% | 5.54% | 5.35% | 5.13% | 4.23% | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | 5.73% | 5.13% | 4.84% | 5.16% | — | — | — | |||||||
UnitedHealth Group Inc. | 4.78% | 4.93% | 5.40% | 8.18% | 7.69% | 7.53% | 7.30% | 8.19% | 7.99% | 7.93% | 7.89% | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | 8.76% | 8.88% | 7.27% | 7.96% | — | — | — |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
ROA = 100
× (Net income attributable to HumanaQ3 2024
+ Net income attributable to HumanaQ2 2024
+ Net income attributable to HumanaQ1 2024
+ Net income attributable to HumanaQ4 2023)
÷ Total assets
= 100 × (480 + 679 + 741 + -541)
÷ 50,007 = 2.72%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Humana Inc. ROA deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |